Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
AditxtScore™ for COVID-19 Now Includes Virus-Specific Infection Blocking Antibodies that Assess the Strength of an Individual’s Immune Response to SARS-CoV-2
RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced enhancements to its AditxtScore™ for COVID-19. A multi-dimensional immune response test that tracks multiple combinations of antibody responses against several different antigens, AditxtScore for COVID-19 has been enhanced to include a high-sensitivity neutralizing antibody diagnostic, which makes it possible to assess the strength of an individual’s immune response to the SARS-CoV-2 virus.
“Everyone’s immune response is unique to that individual. We have been studying individual immune responses to COVID-19 and COVID-19 vaccination, and we are finding that the immediacy, strength, and duration of antibody responses can vary widely based on a multitude of variables,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. “The addition of this new AditxtScore for COVID-19 captures important data on how effective an individual’s antibodies are for inactivating the virus. We believe that as more people become vaccinated or exposed to the virus, AditxtScore for COVID-19 with neutralizing antibody diagnostics adds that next level of precision, delivering more detailed information of the strength of immune response against the virus.”
AditxtScore for COVID-19, which was first introduced in August of 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual’s immune response to multiple antigens associated with the SARS-CoV-2 virus. This multi-multiplex approach to capturing the full spectrum of biomarkers associated with SARS-CoV-2 delivers a highly detailed snapshot of an individual’s immune response in a single test cycle. With this new enhancement, AditxtScore for COVID-19 now includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.
The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotypes, can provide clinicians with the data they need to understand the strength and quality of each individual’s immune response to COVID-19, whether through exposure and infection or vaccination. Furthermore, it allows identification of individuals who are vulnerable to SARS-CoV-2 infection due to absence of previous exposure to the virus or vaccines, but possibly more importantly, due to an inadequate immune response to vaccination or infection. This information is critical for the millions of immunocompromised patients who may not develop an adequate immune response to vaccination or exposure for multiple reasons, including: immunosuppressive disease, immunosuppressant medications, anti-cancer medications affecting immune function, or the presence of long-term chronic disease that has exhausted the body’s natural immune response capacity.
AditxtScore for COVID-19 is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore for COVID-19 is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Media and Investor Relations Contact:
Chief Communications Officer
Source: Aditxt, Inc.